Loading
A few cancer cells survive treatment by going quiet rather than mutating. These survivors are unusually vulnerable to a particular kind of cell death, which a drug could trigger.
Drug-tolerant persister cells adopt a mesenchymal, slow-cycling state that depends on the lipid peroxidase GPX4; their elimination by GPX4 inhibition has been shown in several models across lung, breast and other cancers. Translating this requires a tolerable GPX4 inhibitor or an alternative ferroptosis inducer, and a schedule that applies it during the persister window shortly after maximal response.
Shares Dormant cells and minimal residual disease, Drug resistance (primary and acquired), Acquired resistance to every therapy, Minimal / molecular residual disease (MRD).
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Minimal / molecular residual disease (MRD).
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).